Fernando Sabino M Monteiro
Overview
Explore the profile of Fernando Sabino M Monteiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ciccarese C, Buttner T, Cerbone L, Zampiva I, Monteiro F, Basso U, et al.
Int J Cancer
. 2024 Sep;
155(11):2036-2046.
PMID: 39243397
Metastatic renal cell carcinoma (mRCC) carrying sarcomatoid features (sRCC) has aggressive biology and poor prognosis. First-line immunotherapy (IO)-based combinations have improved the outcome of clear cell RCC patients, including that...
2.
Rizzo A, Buti S, Giannatempo P, Salah S, Molina-Cerrillo J, Massari F, et al.
Clin Exp Metastasis
. 2024 Jun;
41(5):655-665.
PMID: 38850317
Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy...
3.
Fiala O, Buti S, Bamias A, Massari F, Pichler R, Maruzzo M, et al.
Target Oncol
. 2024 May;
19(4):587-599.
PMID: 38704759
Background: About 20% of patients with renal cell carcinoma present with non-clear cell histology (nccRCC), encompassing various histological types. While surgery remains pivotal for localized-stage nccRCC, the role of cytoreductive...
4.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia J, Basso U, et al.
Cancer Immunol Immunother
. 2024 Apr;
73(6):106.
PMID: 38634928
Background: Immune checkpoint inhibitors have changed previous treatment paradigm of advanced urothelial carcinoma (UC). The ARON-2 study (NCT05290038) aimed to assess the real-world effectiveness of pembrolizumab in patients recurred or...
5.
Santoni M, Buti S, Myint Z, Maruzzo M, Iacovelli R, Pichler M, et al.
Eur Urol Oncol
. 2023 Jul;
7(1):102-111.
PMID: 37481365
Background: Renal c carcinoma (RCC) is one of the most common urinary cancers worldwide, with a predicted increase in incidence in the coming years. Immunotherapy, as a single agent, in...
6.
Santoni M, Massari F, Myint Z, Iacovelli R, Pichler M, Basso U, et al.
Target Oncol
. 2023 Jun;
18(4):559-570.
PMID: 37369815
Background: Immuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC). Objective: The ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use...
7.
Santoni M, Myint Z, Buttner T, Takeshita H, Okada Y, Lam E, et al.
Cancer Immunol Immunother
. 2023 May;
72(9):2961-2970.
PMID: 37248424
Background: The advent of immune-checkpoint inhibitors has challenged previous treatment paradigms for advanced urothelial carcinoma (UC) in the post-platinum setting as well as in the first-line setting for cisplatin-ineligible patients....
8.
Santoni M, Massari F, Myint Z, Iacovelli R, Pichler M, Basso U, et al.
Clin Genitourin Cancer
. 2023 Apr;
21(5):e309-e319.e1.
PMID: 37062658
Background: Obesity has been associated with improved response to immunotherapy in cancer patients. We investigated the role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated...
9.
Santoni M, Monteiro F, Massari F, Abahssain H, Aurilio G, Molina-Cerrillo J, et al.
Crit Rev Oncol Hematol
. 2022 Jun;
176:103731.
PMID: 35718065
Statins are commonly prescribed to reduce plasma cholesterol levels and risk of cardiovascular events and mortality. Statin exposure may have cancer-preventive properties in some solid tumors, including Renal Cell Carcinoma...
10.
Monteiro F, Soares A, Souza V, Sperandio R, Grande E, Santoni M, et al.
Clin Genitourin Cancer
. 2022 May;
20(5):391-398.
PMID: 35595632
Nivolumab, a PD-1 ICI has been recently approved for the adjuvant treatment of high-risk MIUC patients. However, conflicting data from another randomized controlled trial (RCT) with atezolizumab makes the benefit...